SCHEMBL16612142

SCHEMBL16612142

CC(C)(C)OC(=O)N1CCC[C@@H](CON)C1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
GLS O94925 2/20 0.50
SCN9A Q15858 1/20 0.48
BACE1 P56817 2/20 0.48
CTSD P07339 1/20 0.48
HPGD P15428 1/20 0.47
FEN1 P39748 2/20 0.46
ALOX5AP P20292 1/20 0.46
ACKR3 P25106 1/20 0.46
CHEK2 O96017 1/20 0.46
NR1H2 P55055 1/20 0.44
KDM1A O60341 1/20 0.44
KAT7 O95251 1/20 0.42
KAT8 Q9H7Z6 1/20 0.42
CYP2C9 P11712 1/20 0.42
EPHX1 P07099 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15208173 1.00 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL695894 0.88 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL22290470 0.88 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL772145 0.88 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL16824002 0.87 MEN1 (0.53) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL26270709 0.87 MEN1 (0.53) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL5191125 0.86 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL640559 0.85 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL481736 0.85 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL1192567 0.85 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059191-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2025-02-20 US disclosed
US-12221443-B2 Crystalline forms of diazabicyclooctane derivative and production process thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2025-02-11 US disclosed
US-12103928-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2024-10-01 US disclosed
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
US-20220348578-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2022-11-03 US disclosed
US-11414417-B2 Crystalline forms of diazabicyclooctane derivative and production process thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2022-08-16 US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
EP-3067355-B1 CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE MEIJI SEIKA PHARMA CO LTD (JP) 2020-12-16 EP disclosed
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-08-17 US disclosed
US-9708320-B2 β-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-07-18 US disclosed
US-20160272641-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-09-22 US disclosed
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-09-15 US disclosed
EP-3067355-A1 CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE Meiji Seika Pharma Co., Ltd. (JP) 2016-09-14 EP disclosed
EP-3050883-A1 PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF Meiji Seika Pharma Co., Ltd. (JP) 2016-08-03 EP disclosed
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-01-28 US disclosed
US-9181250-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-11-10 US disclosed
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-05-21 US disclosed
EP-2857401-A1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME Meiji Seika Pharma Co., Ltd. (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 MEN1 252/4885ALDH1A1 1362/4885MAPT 4296/4885
US-20220348578-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF CCNA1, RCC1, DDT MEN1 793/4885ALDH1A1 1981/4885MAPT 2416/4885
US-20250059191-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF CCNA1, RCC1, DDT MEN1 793/4885ALDH1A1 1981/4885MAPT 2416/4885
US-20160272641-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF DDT, CYP51A1, ODC1 MEN1 880/4885ALDH1A1 2440/4885MAPT 2689/4885
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, MRPL21, FNTB MEN1 1370/4885ALDH1A1 502/4885MAPT 4223/4885
US-12221443-B2 Crystalline forms of diazabicyclooctane derivative and production process thereof CCNA1, RCC1, DDT MEN1 793/4885ALDH1A1 1981/4885MAPT 2416/4885
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, FN1, FNTB MEN1 1708/4885ALDH1A1 466/4885MAPT 4326/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 MEN1 252/4885ALDH1A1 1362/4885MAPT 4296/4885
US-11414417-B2 Crystalline forms of diazabicyclooctane derivative and production process thereof CCNA1, RCC1, DDT MEN1 793/4885ALDH1A1 1981/4885MAPT 2416/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 MEN1 252/4885ALDH1A1 1362/4885MAPT 4296/4885
US-12103928-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 MEN1 252/4885ALDH1A1 1362/4885MAPT 4296/4885
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF CLCN2, ODC1, KCNN4 MEN1 1931/4885ALDH1A1 685/4885MAPT 4807/4885
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME FN1, FNTB, CPN1 MEN1 550/4885ALDH1A1 495/4885MAPT 3671/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 MEN1 252/4885ALDH1A1 1362/4885MAPT 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.